Taken together, these findings indicate that LNMAC plays a crucial role in FGF2‐mediated lymphangiogenesis and lymphatic metastasis, highlighting that LNMAC might be a therapeutic target for lymph node metastasis in CSCC patients. The gene discussed is FGF2; the disease is metastatic malignant neoplasm in the lymph nodes.